Opendata, web and dolomites

NANOSTEM SIGNED

New nanomaterials for neural stem cells drug delivery

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 NANOSTEM project word cloud

Explore the words cloud of the NANOSTEM project. It provides you a very rough idea of what is the project "NANOSTEM" about.

uploading    differentiation    injuries    modeling    skills    hypothesis    wp1    cells    synthesis    groups    cell    pharmaceuticals    stem    ranging    permeation    total    wp3    traumatic    industrial    containing    proliferation    hospital    society    expertise    interdisciplinary    nps    toxicity    clinical    transport    neuroscience    nanomaterials    models    neurodegenerative    modern    regulation    polymer    burden    nanostem    differentiate    biology    vitro    nanoparticles    stroke    computational    team    efficacy    brings    complementary    organic    entrepreneurship    personal    nscs    complemented    animal    train    wp2    wp    union    esrs    strategy    evaluation    seven    translation    packages    nanobiotechnology    associate    bbb    sciences    regenerative    14    neural    diseases    formulations    vivo    scientific    therapeutics    neurons    nanoparticle    professional    pharmacology    six    efficient    tackle    migration    biological    distributed    therapeutic    characterization    chemistry    combined    brain    substantial    full    teams    training    mayor    academic   

Project "NANOSTEM" data sheet

The following table provides information about the project.

Coordinator
QUEEN MARY UNIVERSITY OF LONDON 

Organization address
address: 327 MILE END ROAD
city: LONDON
postcode: E1 4NS
website: http://www.qmul.ac.uk

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Total cost 3˙590˙354 €
 EC max contribution 3˙590˙354 € (100%)
 Programme 1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers)
 Code Call H2020-MSCA-ITN-2017
 Funding Scheme MSCA-ITN-ETN
 Starting year 2018
 Duration (year-month-day) from 2018-06-01   to  2022-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    QUEEN MARY UNIVERSITY OF LONDON UK (LONDON) coordinator 819˙863.00
2    CENTRO DE NEUROCIENCIAS E BIOLOGIACELULAR ASSOCIACAO PT (COIMBRA) participant 715˙069.00
3    UNIVERSITE D'ARTOIS FR (ARRAS) participant 525˙751.00
4    THE UNIVERSITY OF BIRMINGHAM UK (BIRMINGHAM) participant 273˙287.00
5    KAROLINSKA INSTITUTET SE (STOCKHOLM) participant 263˙659.00
6    UNIVERSITAET INNSBRUCK AT (INNSBRUCK) participant 255˙934.00
7    HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH DE (NEUHERBERG) participant 249˙216.00
8    MJR PHARMJET GMBH DE (UBERHERRM) participant 249˙216.00
9    CENTRO HOSPITALAR E UNIVERSITARIO DE COIMBRA E.P.E. PT (COIMBRA) participant 238˙356.00
10    THE UNIVERSITY OF WARWICK UK (COVENTRY) participant 0.00
11    BRAINS FOR BRAIN FOUNDATION ONLUS IT (PADOVA) partner 0.00
12    HCS-Pharma FR (LOOS) partner 0.00
13    UNIVERSIDADE DE COIMBRA PT (COIMBRA) partner 0.00
14    UNIVERSITAT DES SAARLANDES DE (SAARBRUCKEN) partner 0.00

Map

 Project objective

Brain conditions such as neurodegenerative diseases, stroke and traumatic injuries are a mayor burden in modern society. Because neural stem cells (NSCs) can differentiate into new neural cells including neurons, the regulation of their proliferation, differentiation and migration represent a promising regenerative/therapeutic strategy. The hypothesis of NanoStem project is that novel nanoparticles (NPs) combined with recent identified/developed pharmaceuticals can be an efficient approach to control the biological activity of NSCs. The scientific project is organized in three work packages (WP), each focusing on specific objectives and containing well-defined deliverables. WP1 will focus on the synthesis of the nanomaterials and the uploading of the therapeutics. WP2 will take the best nanoparticles and focus more on the evaluation of the permeation and efficacy of the formulations against NSCs. WP3 will focus on in vivo studies to evaluate the formulations developed to tackle the brain and to assess their toxicity. The project will train 14 ESRs in areas including organic and polymer chemistry, cell biology, pharmacology, neuroscience, nanobiotechnology and clinical sciences. The project will also provide a substantial training program in complementary skills, targeting both professional and personal development, and translation of research and entrepreneurship. The project brings together six academic partners, one hospital and two industrial teams as full partners, complemented by four associate partners, one of which is an industrial team, distributed over a total of seven European Union member states. The consortium brings together groups with a very interdisciplinary expertise ranging from nanoparticle synthesis and characterization, computational modeling, in vitro BBB models and BBB transport, neural stem cells, animal testing and clinical expertise.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NANOSTEM" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NANOSTEM" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.1.)

SAMCAPS (2018)

Self-Assembled MicroCAPSules: Synthesis, Characterization, and Eco-friendly Application in Home Care Products

Read More  

INSPIRE (2020)

INnovation in Safety Pharmacology for Integrated cardiovascular safety assessment to REduce adverse events and late stage drug attrition.

Read More  

NU-SPINE (2019)

Training innovative future leaders in research and development of materials and implants for the spine

Read More